{"pmid":32317036,"title":"Bacterial and fungal infections in COVID-19 patients: A matter of concern.","text":["Bacterial and fungal infections in COVID-19 patients: A matter of concern.","Infect Control Hosp Epidemiol","Zhou, Pengcheng","Liu, Zhenguo","Chen, Yuhua","Xiao, Yinzong","Huang, Xun","Fan, Xue-Gong","32317036"],"journal":"Infect Control Hosp Epidemiol","authors":["Zhou, Pengcheng","Liu, Zhenguo","Chen, Yuhua","Xiao, Yinzong","Huang, Xun","Fan, Xue-Gong"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317036","week":"202017|Apr 20 - Apr 26","doi":"10.1017/ice.2020.156","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087755460608,"score":8.518259,"similar":[{"pmid":32307254,"title":"Invasive fungal diseases during COVID-19: We should be prepared.","text":["Invasive fungal diseases during COVID-19: We should be prepared.","J Mycol Med","Gangneux, J-P","Bougnoux, M-E","Dannaoui, E","Cornet, M","Zahar, J R","32307254"],"journal":"J Mycol Med","authors":["Gangneux, J-P","Bougnoux, M-E","Dannaoui, E","Cornet, M","Zahar, J R"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32307254","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.mycmed.2020.100971","keywords":["covid aspergillus","covid pneumocystis","covid aspergillosis","covid fungal","covid mucorales","covid pneumocystosis"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664632501399715840,"score":64.64542},{"pmid":32284617,"title":"Combating COVID-19: health equity matters.","text":["Combating COVID-19: health equity matters.","Nat Med","Wang, Zhicheng","Tang, Kun","32284617"],"journal":"Nat Med","authors":["Wang, Zhicheng","Tang, Kun"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32284617","week":"202016|Apr 13 - Apr 19","doi":"10.1038/s41591-020-0823-6","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664636391586267136,"score":46.627953},{"pmid":32329970,"title":"Rural Matters - Coronavirus and the Navajo Nation.","text":["Rural Matters - Coronavirus and the Navajo Nation.","N Engl J Med","Kovich, Heather","32329970"],"journal":"N Engl J Med","authors":["Kovich, Heather"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329970","week":"202017|Apr 20 - Apr 26","doi":"10.1056/NEJMp2012114","source":"PubMed","weight":0,"_version_":1664996914843615232,"score":46.238564},{"pmid":32246834,"title":"Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.","text":["Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.","An outbreak of 2019-nCoV infection in China has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs, such as interferon-a, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA-dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available.","Clin Pharmacol Ther","Du, Yin-Xiao","Chen, Xiao-Ping","32246834"],"abstract":["An outbreak of 2019-nCoV infection in China has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs, such as interferon-a, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA-dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available."],"journal":"Clin Pharmacol Ther","authors":["Du, Yin-Xiao","Chen, Xiao-Ping"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32246834","week":"202014|Mar 30 - Apr 05","doi":"10.1002/cpt.1844","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Ribavirin","lopinavir-ritonavir drug combination","purine","favipiravir","chloroquine diphosphate"],"_version_":1664638040141725696,"score":44.953266},{"pmid":32255475,"title":"Denominator matters in estimating COVID-19 mortality rates.","text":["Denominator matters in estimating COVID-19 mortality rates.","Eur Heart J","Gaye, Bamba","Fanidi, Anouar","Jouven, Xavier","32255475"],"journal":"Eur Heart J","authors":["Gaye, Bamba","Fanidi, Anouar","Jouven, Xavier"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32255475","week":"202015|Apr 06 - Apr 12","doi":"10.1093/eurheartj/ehaa282","source":"PubMed","weight":0,"_version_":1664640769819934720,"score":44.08105}]}